WALD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Waldencast PLC (WALD) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators are bearish, and there are no significant trading trends or positive signals from proprietary trading tools. While the company has launched a new product with potential in the professional skincare market, the financial performance shows no growth year-over-year, and there is no recent activity from Congress or influential figures to provide additional confidence. A hold is recommended until more positive catalysts or stronger financial growth trends emerge.
The technical indicators for WALD are bearish. The MACD is below zero and negatively expanding, the RSI is neutral at 38.387, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with resistance at 1.86 and support at 1.684.
Obagi Medical, a subsidiary of Waldencast, has launched the ALOHA Program and a new injectable product, Obagi®Saypha®MagIQ™, which utilizes innovative technology and aims to improve patient satisfaction in the professional skincare market.
The company's financials show no year-over-year growth in revenue, net income, or EPS. Additionally, technical indicators are bearish, and there are no significant trading trends from hedge funds or insiders.
In Q1 2025, Waldencast PLC reported revenue of $65,442,000, net income of $0, and EPS of -1.51. These metrics showed no growth year-over-year. The gross margin was 69.91%, also unchanged.
No data available for analyst ratings or price target changes.
